A Multicenter, Open-label, Single-arm Study to Demonstrate the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Chinese Subjects Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate-, Posterior-, or Pan-uveitis
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 24 Jun 2024 Status changed from active, no longer recruiting to completed.
- 21 Sep 2023 Planned End Date changed from 10 Nov 2024 to 20 Jun 2024.
- 21 Sep 2023 Planned primary completion date changed from 10 Nov 2024 to 20 Jun 2024.